Skip to main content
An official website of the United States government
Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Funded Symptom Science Grants

PI Name Sort descending PI Organization Title Grant Number Program Official
Buczynski, Matthew Wallace

Virginia Polytechnic Inst And St Univ
United States

Anti-nociceptive actions of CART II in chemotherapy-induced peripheral neuropathy 5R01CA284075-03 Rachel Altshuler, Ph.D.
Buczynski, Matthew Wallace

Virginia Polytechnic Inst And St Univ
United States

Anti-nociceptive actions of CART II in chemotherapy-induced peripheral neuropathy 5R01CA284075-03 Rachel Altshuler, Ph.D.
Butler, Kathleen Yost

Corewell Health
United States

Cancer Research Consortium of West Michigan (CRCWM) 3UG1CA189860-11S1 Vanessa A. White, M.P.H.
Butler, Kathleen Yost

Corewell Health
United States

Cancer Research Consortium of West Michigan (CRCWM) 3UG1CA189860-11S1 Vanessa A. White, M.P.H.
Cantuaria, Guilherme

Northside Hospital Atlanta
United States

Georgia NCI Community Oncology Research Program (GA NCORP) 3UG1CA189997-11S1 Vanessa A. White, M.P.H.
Cantuaria, Guilherme

Northside Hospital Atlanta
United States

Georgia NCI Community Oncology Research Program (GA NCORP) 3UG1CA189997-11S1 Vanessa A. White, M.P.H.
Cao, Weidan

Ohio State University
United States

Treatment-Related Cardiotoxicity Risk Prediction for Breast Cancer Patients with a Multimodal AI-based System 1R01CA301579-01 Eileen Dimond, R.N., M.S.
Cao, Weidan

Ohio State University
United States

Treatment-Related Cardiotoxicity Risk Prediction for Breast Cancer Patients with a Multimodal AI-based System 1R01CA301579-01 Eileen Dimond, R.N., M.S.
Carlson, Jay W

Ozark Health Ventures, Llc
United States

Ozark Health Ventures LLC dba Cancer Research for the Ozarks (CRO) 3UG1CA189822-11S1 Vanessa A. White, M.P.H.
Carlson, Jay W

Ozark Health Ventures, Llc
United States

Ozark Health Ventures LLC dba Cancer Research for the Ozarks (CRO) 3UG1CA189822-11S1 Vanessa A. White, M.P.H.
Caywood, Emi H

Nemours Children'S Hospital, Delaware
United States

Nemours NCI Community Oncology Research Program (NCORP) 3UG1CA189958-11S1 Vanessa A. White, M.P.H.
Caywood, Emi H

Nemours Children'S Hospital, Delaware
United States

Nemours NCI Community Oncology Research Program (NCORP) 3UG1CA189958-11S1 Vanessa A. White, M.P.H.
Chan, Alexandre

University Of California-Irvine
United States

Neurotrophic strategy to mitigate chemotherapy-related brain injury 5R01CA276212-03 John Clifford, Ph.D.
Chan, Alexandre

University Of California-Irvine
United States

Neurotrophic strategy to mitigate chemotherapy-related brain injury 5R01CA276212-03 John Clifford, Ph.D.
Cheville, Andrea Lynne

Mayo Clinic Rochester
United States

Achieving Safe, Comprehensive, Digitally-Enabled Cancer Pain managemeNT” (ASCENT) Clinical Trial 5R33CA278594-04 Brennan Streck, Ph.D., RN, M.P.H.